E
60 Degrees Pharmaceuticals, Inc. SXTP
$0.238 $0.00040.17%
Recommendation
Sell
Prev Close
$0.241
Volume
350
Avg Vol (90D)
620,278
Market Cap
$2.79M
Dividend & Yield
--
52-Week Range
$0.222 - $8.65
P/E (TTM)
--
EPS (TTM)
-$2.09
My Lists My Alerts
Report
Rating
Reward
E-
Very Weak
Risk
D-
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Fair
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Rating Reiterated by HC Wainwright
4/7/2024 - Ticker Report
HC Wainwright Analysts Increase Earnings Estimates for 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP)
4/5/2024 - Ticker Report
60 Degrees Pharmaceuticals to sponsor pilot study of tafenoquine
4/3/2024 - The Fly
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
4/3/2024 - Globe Newswire
60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
4/3/2024 - Simply Wall St
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
4/3/2024 - TipRanks Financial Blog
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
4/3/2024 - TipRanks Financial Blog
Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Decreases By 56.9%
3/28/2024 - Ticker Report
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Stock Holdings Trimmed by Central Bank & Trust Co.
3/17/2024 - Zolmax
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
3/14/2024 - Globe Newswire
Short Interest in 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Drops By 50.5%
2/29/2024 - Ticker Report
60 Degrees Pharmaceuticals to sponsor pre-clinical studies of Tafenoquine use
2/20/2024 - The Fly
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
2/20/2024 - Globe Newswire
60 Degrees Pharmaceuticals appoints Kristen Landon as CCO
2/8/2024 - The Fly
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
2/8/2024 - Globe Newswire
H.C. Wainwright Sticks to Their Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)
2/2/2024 - TipRanks Financial Blog
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
1/31/2024 - PR Newswire
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
1/31/2024 - Globe Newswire
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
1/30/2024 - PR Newswire
60 Degrees Pharmaceuticals stock sinks on pricing of $2.4M public offering
1/30/2024 - Seeking Alpha - Healthcare
60 Degrees Pharmaceuticals prices 5.26M units at 38.5c in public offering
1/30/2024 - The Fly
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
1/30/2024 - Globe Newswire
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Shares Down 25%
1/25/2024 - Zolmax
60 Degrees Pharmaceuticals files to sell 4.79M units
1/22/2024 - The Fly
60 Degrees Pharmaceuticals, Inc. (SXTP) Gets a Hold from H.C. Wainwright
1/22/2024 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$253.60K
EBITDA (TTM)
-$5.10M
EBIT (TTM)
-$5.15M
Net Income (TTM)
-$3.77M
Balance Sheet
Total Assets (Q)
$7.78M
Total Debt (Q)
$172.70K
Total Liabilities (Q)
$2.99M
Book Value Per Share (Q)
-$0.8585
Cash Flow
Cash from Operations (TTM)
-$4.54M
Cash from Investing (TTM)
-$115.90K
Cash from Financing (TTM)
$6.47M
Net Change in Cash (TTM)
$1.88M
Filings
Filing Date
Monday, April 1, 2024
Period Date
Sunday, December 31, 2023
Next Filing
Week of May 13 and 17 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-5.48%
30-Day Total Return
-2.86%
60-Day Total Return
-15.12%
90-Day Total Return
-65.95%
Year to Date Total Return
-76.89%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Mar 14, 2024 - $0.222
52-week High
Jul 13, 2023 - $8.65
Valuation
Market Cap
$2.79M - Nano Cap
Enterprise Value
$10.60M
Price/Sales (TTM)
5.53
Price/Book (Q)
-0.28
Dividends and Shares
Shares Outstanding
5.81M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.60degreespharma.com
Phone Number
202-327-5422
Address
1025 Connecticut Avenue NW
Washington, DC 20036
Country
United States
Year Founded
2010
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the... more
NASDAQ 04/29/2024 3:52PM Eastern Quotes delayed
Weiss Ratings